(Q40884087)

24 September 2017

Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice (English)

1 reference

24 September 2017

anti-retroviral agent

0 references

author name string

Moyle GJ

series ordinal

1

1 reference

PubMed ID

15989655

24 September 2017

language of work or name

English

0 references

publication date

1 August 1997

1 reference

Expert Opinion on Investigational Drugs

24 September 2017

1 reference

24 September 2017

6

1 reference

24 September 2017

8

1 reference

24 September 2017

943-964

1 reference

Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions

24 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Perspective: research highlights at the Albert Einstein College of Medicine Center for AIDS research. Approaches to control drug resistance in HIV: the role of increased polymerase fidelity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Identification of the nucleotide binding site of HIV-1 reverse transcriptase using dTTP as a photoaffinity label

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Characterization of genetic variation and 3'-azido-3'-deoxythymidine- resistance mutations of human immunodeficiency virus by the RNase A mismatch cleavage method

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Functional domains of transcription factor TFIIB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Detection of Mutations Associated with Zidovudine Resistance in Human Immunodeficiency Virus by Use of the Polymerase Chain Reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Biological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Human immunodeficiency virus reverse transcriptase codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon- A Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Active human immunodeficiency virus protease is required for viral infectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Current knowledge and future prospects for the use of HIV protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Clinical isolates of HIV-1 contain few pre-existing proteinase inhibitor resistance-conferring mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

To sequence or not to sequence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Structures of DNA and RNA polymerases and their interactions with nucleic acid substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

In vivo comparison of zidovudine resistance mutations in blood and CSF of HIV-1-infected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Development and significance of zidovudine resistance in children infected with human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

HIV-1 sensitivity to zidovudine and clinical outcome in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequential blood samples and various organs obtained at autopsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

HIV-1 Reverse Transcriptase Codon 215 Mutation and Clinical Outcome in Children Treated with Zidovudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.6.8.943

21 January 2018

Identifiers

DOI

10.1517/13543784.6.8.943

1 reference

24 September 2017

1 reference

PubMed ID

15989655